Fundraising FoxHBM Healthcare Investments
Crossover fundZug · Growth · 8 people tracked
Find your way into HBM Healthcare Investments
Sign up to see every warm intro you have to HBM Healthcare Investments
- Paths you didn't know you had: your email and LinkedIn already hold routes to the HBM Healthcare Investments team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
HBM Healthcare Investments invests globally in the healthcare sector, building a diversified portfolio spanning private and publicly listed companies. The firm views healthcare as an attractive, fast-growing investment universe driven by demographic trends such as population growth and aging, ongoing medical progress and innovation, rising prosperity in emerging markets, and improved access to medical products and services. Persistent demand for new therapies across a growing range of diseases and continuous innovation in products, services and business models underpin the strategy. As a listed company (HBMN), it has delivered attractive NAV and share price performance alongside a distribution yield of roughly 3 to 5 percent per year.
Source: firm website, verified Sep 27, 2026.
Team · 8 people
from the firm's website & public directories
Physician-investor with over twenty years of experience across private equity, clinical practice, and biomedical research. Holds an MD from Freie Universität Berlin (Charité), an MAS in Medicines Development from the University of Basel, and an MBA from INSEAD; previously a Stanford postdoctoral scientist, physician at University Hospital Leipzig, and principal at Wellington Partners. Serves as board member of Dren Bio, Fore Biotherapeutics, Monte Rosa, and River Renal, and board observer at Karius.
Elaine V. Jones holds a doctorate in microbiology from the University of Pittsburgh and a B.Sc. from Juniata College. She previously worked as a research scientist and Director of Scientific Licensing at SmithKline Beecham, Vice President at S.R. One (GlaxoSmithKline's corporate fund), General Partner at EuclidSR Partners, and Vice President at Pfizer Ventures. She has served on the board of directors of HBM Healthcare Investments since 2021.
Hans Peter Hasler has chaired the board of directors of HBM Healthcare Investments since 2009 and serves on its audit committee. He was CEO of Vicarius Pharma from 2017 to 2020 and previously held international leadership roles at Wyeth Pharmaceuticals, Biogen Inc., and Elan Corporation. He holds a Swiss federal commercial diploma and a marketing certificate from the Schweizerisches Institut für Betriebsökonomie (SIB) in Zurich.
Mario G. Giuliani is an economist who has served on the board of directors of HBM Healthcare Investments since 2012, where he is a member of the compensation and nomination committees. He previously held executive positions and board mandates at companies including Giuliani SpA, Recordati SpA, Nogra Group SA, Fair-Med Healthcare AG and Jukka LLC. He also holds board roles at several investment and family office entities and is a Swiss national.
Dr. Rudolf Lanz is an economist with a doctorate in law who has served on the board of directors of HBM Healthcare Investments since 2003 and sits on its audit committee. He previously worked as a consultant, executive committee member and partner at Ernst & Young AG from 1980 to 2000, and co-founded The Corporate Finance Group AG, where he was partner and chairman from 2000 to 2009. He holds Swiss nationality.
Stella Xu has served on the board of directors of HBM Healthcare Investments since 2020, sitting on its compensation and nomination committees. She holds a doctorate in immunology from Northwestern University and a degree in biophysics from Peking University, and has been managing director of Quan Capital since 2017. Her earlier career included roles at Roche (2002–2017), McKinsey & Company (1998–2002), and Ionis Pharmaceuticals (1996–1998).
What they invest in
from 50 of 65 portfolio companiesBiotech ×40Healthtech ×37Medical Devices ×20AI & Machine Learning ×8Digital Health ×8Deep Tech ×6E-commerce ×3B2B Marketplaces ×1
HQs:United States×35Germany×2Switzerland×1China×1India×1Italy×1
Who they back
founder profiles across 24 portfolio companiesFounding team size:solo founder×172 founders×43 founders×24+ founders×1
Where their founders studiedfrom 20 founders with education data
Massachusetts Institute of Technology ×3Dartmouth College ×2
What their founders studiedfrom 17 founders with field-of-study data
Life Sciences ×7Engineering ×5Computer Science ×2Physics ×2
10 founders hold a PhD · 2 hold an MBA (of 20 with degree data)
Investments · 65 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12024 · 12022 · 32021 · 22020 · 32019 · 12018 · 12017 · 52016 · 22015 · 122 dated
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)inJack Danilkowicz(Chief Commercial Officer)inJörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in
Co-investorsForesite CapitalGeneral AtlanticHBM PartnersNextech InvestOrbiMedSamsara BioCapital+4 more
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone Venturesage1Foresite CapitalHBM PartnersvenBio PartnersLogos+1 more
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Harmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases.
BiotechHealthtechMedical DevicesNorthbrook, US
Jeffrey Aronin(Director)inJeffrey M. Dayno, M.D.(President and Chief Executive Officer)inPatrick Morris(Secretary and Treasurer)inRobert Repella(Director and Chief Executive Officer)Darien Parhad(Chief Financial Officer)
BoardAaron Royston(Director)in
Co-investorsAisling CapitalHBM PartnersParagon Biosciences LLCPivotal Life SciencesValor Equity PartnersvenBio Partners+3 more
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Co-investorsAndera PartnersHBM PartnersSamsara BioCapitalSR One Capital ManagementYsios CapitalAdams Street Partners+3 more
Monte Rosa develops molecular glue degrader (MGD) therapeutics using MGD chemistry, artificial intelligence, structural biology, and proteomics to target previously undruggable or inadequately drugged disease targets.
AI & Machine LearningBiotechDeep TechHealthtechBoston, US
Markus Warmuth(Chief Executive Officer)inSharon Townson(Ph.D., Chief Scientific Officer)inJohn Castle(Ph.D., Chief Data and Information Officer)inFilip Janku(M.D., Ph.D., Chief Medical Officer)inPhil Nickson(Ph.D., J.D., Chief Business and Legal Officer)inMagnus Walter(DPhil, Chief Technology Officer)in
Co-investorsAisling CapitalHBM PartnersNew Enterprise Associates (NEA)Versant VenturesAmzak HealthAvoro Capital Advisors+4 more
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)inJonathan Sheena(Founder)inSteven Chapman(Chief Executive Officer & President)
Co-investorsBain Capital Life SciencesCheyenne VenturesClaremont Creek VenturesForesite CapitalHarmony PartnersLightspeed Venture Partners+4 more
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)in
Co-investorsARCH Venture PartnersCatalio Capital Management, LPDeerfield Management CompanyForesite CapitalFrazier Life SciencesGeneral Catalyst+9 more
.png)
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Partners+5 more
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsBrace PharmaCTI Life Sciences Fund L.P.Lumira VenturesNextech InvestWUTIF CapitalAmplitude Venture Capital
1000Farmacie is an Italian online pharmacy and parapharmacy marketplace that aggregates products from over 60 partner pharmacies and other sellers, offering over 100,000 products for health and wellness including pharmaceuticals, medical devices, veterinary medicines, homeopathic and ayurvedic products, with home delivery across Italy.
B2B MarketplacesE-commerceHealthtechItaly, IT
Nicolo Petrone(Founder)inAlberto Marchetti(Founder)in
Co-investorsClub degli InvestitoriHBM PartnersItalian Angels for GrowthLIFTTP101 Ventures
This is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth.
Digital HealthE-commerceHealthtechIndia, IN
Gaurav Agarwal(Founder)Prashant Tandon(Founder)Vikas Chauhan(Founder)
Co-investorsHBM PartnersKae CapitalLeo Capital VenturesPeak XV PartnersSpring Marketing CapitalVenturEast+3 more
AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication.
BiotechHealthtechMedical DevicesHennigsdorf, DE
Gerald Moeller(Co-founder and former CEO of AdrenoMed; Supervisory Board member)inRichard Jones(Chief Executive Officer (CEO))inDavid Germonpré(Chief Financial Officer (CFO))in
Co-investorsBrandenburg KapitalCatalyze CapitalHBM PartnersVU Venture Partners
Amphora provides logistics services aimed at supporting business growth and operational efficiency.
E-commerceLogistics & Supply ChainSaaS
Joan Tresserras(Founder)inAdrià Cortés(Founder)in
Co-investorsBStartupLongitude CapitalBaird CapitalF-Prime Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesBrace PharmaCanaan PartnersGaingelsGV (Google Ventures)+6 more
__Twitter.png)
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent Capital+3 more
The company develops therapies for people with severe autoimmune diseases.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsBioGeneration VenturesMPM BioImpactPMVSeventure PartnersAescap Life Sciences+2 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesHBM PartnersNextech InvestOUP (Osage University Partners)+2 more
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHBM PartnersHongShan Capital GroupLAV+4 more
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).
BiotechHealthtechMedical DevicesSan Diego, US
Jay M. Short(Executive Officer, Director)Richard A. Waldron(Executive Officer)inCarolyn Short(Director)
Co-investorsKeshif VenturesPappas CapitalPfizer Venture InvestmentsPappas CapitalPfizer VenturesSoleus Capital
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)OrbiMed
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsFrazier Life SciencesRA CapitalRiverVest Venture PartnersWellington ManagementFrazier Healthcare PartnersNovo Holdings+2 more
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers.
BiotechHealthtechMedical Devices
Azim Surani(Co-founder)
Co-investorsAvego BioScience CapitalFuture Planet CapitalHBM PartnersRA CapitalSofinnova PartnersBrightEdge+3 more
connectRN operates a mobile app marketplace that matches nurses and clinicians with open shifts at healthcare facilities such as hospitals, home health, and hospice across the US.
Future of WorkHealthtechHR TechMarketplacesWaltham, US
Ted Jeanloz(Executive Officer)in
BoardMichael Jasulavic(Director)John Pappajohn(Director)Geoffrey Harris(Director)Idriz Limaj(Director)
Co-investorsData Point CapitalHBM Partners
Develops therapies for cardiometabolic conditions.
Co-investorsNew Enterprise Associates (NEA)RA CapitalRTW Investments L.P.
Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.
BiotechHealthtechBothell, US
George Simeon(CEO)inGregory S. Curhan(CFO)Guy De La Rosa(CMO)in
Co-investorsAdjuvant CapitalMedicxiOrbiMedRA CapitalSanofi VenturesJanus Henderson Investors
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Founder)
BoardIvan Trifunovich(Director)John Wesley(Founder)
Co-investors8VCAisling CapitalHBM PartnersJacket River Capital PartnersMission Bay CapitalMission Biocapital+5 more
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPHBM PartnersKhosla VenturesLifeSci Venture Partners+12 more
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Adam Rosenthal(Co-founder and former CEO; Director)inQuehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)Kathy Dong(President, Chief Executive Officer and Director)in
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)
Co-investorsHBM PartnersOrbiMedRA CapitalWestlake Village BioPartnersKleiner PerkinsNVIDIA
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsHBM PartnersLG Technology VenturesNovartis Venture FundOrbiMedPontifax Venture CapitalSR One Capital Management+4 more
Genalyte develops Merlin, a real-time diagnostic system that performs laboratory testing directly in clinical settings and integrates results with electronic health records.
Digital HealthHardwareHealthtechMedical DevicesSan Diego, US
Cary Gunn(Founder)in
Co-investorsBioBritBoutique Venture PartnersClaremont Creek VenturesCLI VenturesFusionX VenturesHBM Partners+7 more
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)AlexandriaDeerfield Management CompanyFidelity Investments+5 more
IOBiotech appears to be a biotech company focused on oncology, with a founder who has extensive experience in cancer drug development and clinical advancement from roles at Roche, Eli Lilly, and leading academic cancer centers.
BiotechMedical Devices
Dr. Dhingra
Co-investorsAvoro Capital AdvisorsEIR VenturesKurma PartnersPivotal Life SciencesRA CapitalSamsara BioCapital+3 more
Karius is a company that provides microbial cell-free DNA (mcfDNA) metagenomic sequencing services for research and clinical applications.
AI & Machine LearningBiotechDigital HealthMedical DevicesSan Francisco, US
Alec Ford(Chief Executive Officer)inMickey Kertesz(Founder)Stephen Quake(Founder)Tim Blauwkamp(Founder)
Co-investors5AM VenturesDCVC (Data Collective)HBM PartnersKhosla VenturesLightspeed Venture PartnersSeventure Partners+3 more
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Carolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAetna Wun Trombley(President and CEO)inAmy Bachrodt(Chief Financial Officer)inChin Lee(Chief Medical Officer)inSteve Staben(Chief Scientific Officer)inSofia Touami(Chief Business Officer)in
Co-investorsREDMILEVersant VenturesHBM PartnersBAM ElevateFranklin TempletonInvus+5 more
Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners.
BiotechHealthtechSouth San Francisco, US
Yael Weiss(Chief Executive Officer)in
BoardCamille Samuels(Director)inMarten Steen(Director)inShalini Sharp(Director)inStephen Farr(Director)
Co-investorsDroia VenturesHBM PartnersHealthCapMitsui Global InvestmentVenrock
Neurelis is a neuroscience-based biopharmaceutical company that develops treatments for people living with neurological conditions such as epilepsy.
BiotechHealthtechMedical DevicesEncinitas, US
Craig Chambliss(Founder)in
BoardDavid F. Hale(Director)Cam Garner(Director)Yong Zhang(Director)Kevin Li(Director)in
Co-investorsHBM PartnersLYZZ CapitalOrbiMed
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsHBM PartnersKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartnersACORN BIOVENTURES+2 more
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalHBM PartnersLAVLilly Asia VenturesRA CapitalSamsara BioCapital+3 more
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety.
BiotechDeep Tech
David Urech(Founder)in
Co-investorsEisai Innovation, Inc.HBM PartnersBiotechnology Value FundBlackRockForbionNovo Holdings+1 more
Shape Memory Medical develops embolization and occlusion medical devices built on a bioabsorbable shape memory ("smart") polymer that expands to conform to vascular anatomy.
HealthtechSan Jose, US
Duncan Maitland(Director)inMichael Henson(Executive Officer, Director)inEdward F. Ruppel, Jr(Executive Officer, Director)Carolyn M. Bruguera(Executive Officer)James Y Lancaster(Executive Officer, Director)in
BoardThom Rasche(Director)
Co-investorsEmergent Medical Partners, LLPHBM PartnersEarlybird Venture CapitalTaiwania Capital
SphingoTec develops proprietary biomarkers for critical care diagnostics, addressing acute kidney injury, sepsis, and acute heart failure through partnerships with in vitro diagnostics companies and pharmaceutical firms.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHennigsdorf, DE
Deborah Bergmann(Chief Executive Officer)in
Co-investorsBrandenburg KapitalHBM Partners
Swixx BioPharma is a specialized pharmaceutical distributor and market access partner that represents international biopharma, OTC, and medical device companies in markets across Central & Eastern Europe, the Middle East, North Africa, Latin America, and Eurasia.
BiotechHealthtechMedical DevicesBaar, CH
Co-investorsBain Capital Life SciencesHBM PartnersSK Capital PartnersMérieux Equity Partners
Valo Health applies technology and data to drug discovery, working across the technology, biotech, and healthcare fields.
AI & Machine LearningBiotechHealthtech
David Berry(Founder)in
Co-investorsAtinum Investment Co. Ltd.BioGenerator VenturesFlagship PioneeringHBM PartnersKoch Disruptive TechnologiesWestern Technology Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADARxAmphora MedicalBaseHealthC-Ray TherapeuticsCathay BiotechComplexaCorvidia TherapeuticsCORXEL PharmaceuticalsCrystlaysCure Everlife HoldingsFangzhou / JiankeFarmalatamIgnis TherapeuticsNuance BiotechOnesourceRiver RenalSpringWorks TherapeuticsSwixx HealthcareSymbiomix TherapeuticsVascular DynamicsVisen Pharma
Exits · 15
11 IPOs · 4 acquisitions · showing 12AlumisNASDAQ: ALMSAlx OncologyNASDAQ: ALXOFreenomeNASDAQ: FRNMHarmony BiosciencesNASDAQ: HRMYMineralys TherapeuticsNASDAQ: MLYSMonte Rosa TherapeuticsNASDAQ: GLUENateraNASDAQ: NTRAParabilis MedicinesNASDAQ: PBLSUpstream BioNASDAQ: UPBZymeworksNASDAQ: ZYMEAmphora Medicalacq. by HologicBluejaytxacq. by Mirum Pharmaceuticals
Portfolio news
latest coverage across their companies
Arrivent · stocktitan.net · Aug 12, 2026
Upstream Bio · stocktitan.net · Aug 11, 2026
Fore Biotherapeutics · technical.ly · Aug 6, 2026
Lycia Therapeutics · finsmes.com · Jun 29, 2026
Arrakis Therapeutics · biospace.com · Jun 25, 2026
arGEN-X · umbrex.com · Jun 5, 2026
CellCentric · finsmes.com · May 6, 2026
Dren Bio · biospace.com · Mar 2, 2026
Frequently asked questions
- How many investments has HBM Healthcare Investments made?
- HBM Healthcare Investments has 65 tracked investments, 15 of which have exited, including 3 dated in the last 24 months.
- What stage does HBM Healthcare Investments invest at?
- HBM Healthcare Investments invests at the Growth stage.
- What sectors does HBM Healthcare Investments focus on?
- HBM Healthcare Investments focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is HBM Healthcare Investments located?
- HBM Healthcare Investments is headquartered in Zug, CH.
- Does HBM Healthcare Investments lead rounds?
- HBM Healthcare Investments has led 3 of the 14 rounds where its role is on record.
- Who does HBM Healthcare Investments co-invest with?
- HBM Healthcare Investments most often shares deals with HBM Partners, OrbiMed, RA Capital, among 131 tracked co-investors.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
JAZZ Venture Partners is a venture capital firm investing in early- and growth-stage companies at the intersection of technology, science, and human performance across enterprise, wellness, healthcare, and consumer markets.
Lauder Partners is the venture investment vehicle of Gary Lauder, investing in early- and growth-stage private companies across a broad range of technology, healthcare, energy and consumer sectors.